{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T09:11:00Z","timestamp":1760778660683,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2021HXBH024","ZYGD18012"],"award-info":[{"award-number":["2021HXBH024","ZYGD18012"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M692267"],"award-info":[{"award-number":["2021M692267"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.breast.2022.03.019","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T07:31:26Z","timestamp":1648711886000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy"],"prefix":"10.1016","volume":"64","author":[{"given":"Libo","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-6443","authenticated-orcid":false,"given":"Hong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.breast.2022.03.019_bib1","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6797","key":"10.1016\/j.breast.2022.03.019_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.breast.2022.03.019_bib3","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.breast.2022.03.019_bib4","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2022.03.019_bib5","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1158\/1078-0432.CCR-12-0286","article-title":"A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen","volume":"18","author":"Chia","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9805","key":"10.1016\/j.breast.2022.03.019_bib6","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","article-title":"Gene expression profiling in breast cancer: classification, prognostication, and prediction","volume":"378","author":"Reis-Filho","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.breast.2022.03.019_bib7","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2022.03.019_bib8","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1245\/s10434-014-3851-y","article-title":"Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement","volume":"21","author":"Ugras","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.breast.2022.03.019_bib9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdn675","article-title":"Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland","volume":"20","author":"Spitale","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.breast.2022.03.019_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/bcr623","article-title":"The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification","volume":"5","author":"Pinder","year":"2003","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2022.03.019_bib11","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2128","article-title":"Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer","volume":"10","author":"Tamimi","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2022.03.019_bib12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00432-018-2697-2","article-title":"Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database","volume":"144","author":"Kim","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.breast.2022.03.019_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41523-020-0167-x","article-title":"Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions","volume":"6","author":"Bergholtz","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.breast.2022.03.019_bib14","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/PAS.0000000000001306","article-title":"Discordant marker expression between invasive breast carcinoma and corresponding synchronous and preceding DCIS","volume":"43","author":"Visser","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"10.1016\/j.breast.2022.03.019_bib15","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-19-2563","article-title":"Whole-exome sequencing analysis of the progression from non-low-grade ductal carcinoma in situ to invasive ductal carcinoma","volume":"26","author":"Pareja","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2022.03.019_bib16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.molonc.2013.07.005","article-title":"Progression from ductal carcinoma in situ to invasive breast cancer: revisited","volume":"7","author":"Cowell","year":"2013","journal-title":"Mol Oncol"},{"issue":"7","key":"10.1016\/j.breast.2022.03.019_bib17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.breast.2022.03.019_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1245\/s10434-020-09003-6","article-title":"Prognostic score-based stratification analysis reveals universal benefits of radiotherapy on lowering the risk of ipsilateral breast event for ductal carcinoma in situ patients with different risk levels","volume":"28","author":"Yang","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9169","key":"10.1016\/j.breast.2022.03.019_bib19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: national Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.breast.2022.03.019_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JCO.2020.38.15_suppl.508","article-title":"Primary results of NRG Oncology\/NSABP B-43: phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy","volume":"38","author":"Cobleigh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.03.019_bib21","unstructured":"National Cancer Institute: surveillance, Epidemiology, and End Results Program. http:\/\/seer.cancer.gov\/."},{"issue":"11","key":"10.1016\/j.breast.2022.03.019_bib22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2015.65.1869","article-title":"Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study","volume":"34","author":"Sagara","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2022.03.019_bib23","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1073\/pnas.1108781108","article-title":"Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling","volume":"109","author":"Kristensen","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.breast.2022.03.019_bib24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","article-title":"Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer","volume":"16","author":"Lesurf","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.breast.2022.03.019_bib25","article-title":"DCIS genomic signatures define biology and correlate with clinical outcome: a Human Tumor Atlas Network (HTAN) analysis of TBCRC 038 and RAHBT cohorts","author":"Strand","year":"2021","journal-title":"bioRxiv"},{"issue":"31","key":"10.1016\/j.breast.2022.03.019_bib26","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2022.03.019_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-013-2755-z","article-title":"Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43","volume":"142","author":"Siziopikou","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2022.03.019_bib28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/path.4840","article-title":"Genome evolution in ductal carcinoma in situ: invasion of the clones","volume":"241","author":"Casasent","year":"2017","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.breast.2022.03.019_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00428-014-1609-3","article-title":"Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype","volume":"465","author":"Van Bockstal","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.breast.2022.03.019_bib30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12885-015-1479-3","article-title":"The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study","volume":"15","author":"Borgquist","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.breast.2022.03.019_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-014-2983-x","article-title":"Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer","volume":"145","author":"Lee","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.breast.2022.03.019_bib32","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.breast.2022.03.019_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00428-018-2416-z","article-title":"Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile","volume":"473","author":"Takahashi","year":"2018","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.breast.2022.03.019_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13277-012-0602-1","article-title":"In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer","volume":"34","author":"Kurbel","year":"2013","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.breast.2022.03.019_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2022.03.019_bib36","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10021","key":"10.1016\/j.breast.2022.03.019_bib37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","article-title":"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Ganz","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2022.03.019_bib38","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.2011.40.5514","article-title":"Refining the use of endocrine therapy for ductal carcinoma in situ","volume":"30","author":"Morrow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.03.019_bib39","article-title":"The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast [abstract]","volume":"79","author":"Lewis","year":"2018"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762200073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762200073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:44:30Z","timestamp":1760777070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762200073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":39,"alternative-id":["S096097762200073X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.03.019","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}